TY  - JOUR
AU  - Civan, Caner
AU  - Karpinski, Madeleine J
AU  - Rahbar, Kambiz
AU  - Fendler, Wolfgang P
AU  - Herrmann, Ken
TI  - The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects.
JO  - Seminars in nuclear medicine
VL  - nn
SN  - 0001-2998
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-03061
SP  - nn
PY  - 2025
N1  - epub
AB  - PSMA-PET has become a pivotal imaging method for staging and restaging of prostate cancer. Risk stratification of the disease is a crucial for the patients to receive most appropriate treatment, and for the clinicians to follow the patients more precisely. PSMA-PET provides non-invasive biomarkers for the risk assessment of prostate cancer, offering prediction of clinical outcomes. PROMISE criteria have been developed as comprehensive and integrated framework demonstrating association with overall survival. In this review, we aim to provide a brief update of the prognostic value of PSMA-PET for risk assessment in prostate cancer.
KW  - Assessment (Other)
KW  - CT (Other)
KW  - PET (Other)
KW  - PSMA (Other)
KW  - Prostate cancer (Other)
KW  - Risk (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41453817
DO  - DOI:10.1053/j.semnuclmed.2025.12.003
UR  - https://inrepo02.dkfz.de/record/307462
ER  -